ANI Pharma Inc (ANIP) 56.27 $ANIP Anavex's Lead

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 11:12 PM

ANI Pharma Inc (ANIP) 56.27 $ANIP

Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 4.27 (+0.12), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Incyte Reports Epacadostat Combination Study Initiation
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 9:59AM CDT
Incyte (INCY) reported that the first patient has been treated in a phase III epacadostat combination study for advanced or metastatic melanoma.
ANIP: 56.27 (+3.48), INCY: 81.66 (+3.16), MRK: 57.68 (+0.64), BMY: 72.64 (+0.33)

Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), RTRX: 18.49 (+0.01), NYMX: 2.91 (-0.24)

Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), EPZM: 10.44 (-0.28)

Pluristem Therapeutics (PSTI) Catches Eye: Stock Up 11.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:15AM CDT
Pluristem Therapeutics, Inc. (PSTI) shares rose almost 12% in the last trading session.
ANIP: 56.27 (+3.48), PSTI: 1.36 (+0.01)

Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 1.03 (+0.01), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), CELG: 100.66 (+1.43)

GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 89.14 (+0.57), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)

RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:11AM CDT
RedHill (RDHL) announced positive results from a phase I study on Yeliva for the treatment of advanced solid tumors.
RDHL: 10.87 (+0.15), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 3:51PM CDT
Inovio Pharmaceuticals (INO) and GeneOne Life Science will begin the first Zika vaccine study in human volunteers; Inovio's stock gains.
INO: 9.85 (-0.35), ANIP: 56.27 (+3.48), XON: 25.20 (+0.55), RTRX: 18.49 (+0.01)

Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.83 (unch), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 83.37 (+0.92), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)

Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:12AM CDT
Vical (VICL) presented data from a phase I/II study on its investigational genital herpes vaccine at a meeting of the American Society for Microbiology.
VICL: 4.60 (+0.24), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

Sunesis Pharmaceuticals (SNSS) in Focus: Stock Gains 8.7%
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:45AM CDT
Sunesis Pharmaceuticals, Inc. (SNSS) was a big mover last session, as the company saw its shares rise over 8% on the day.
ANIP: 56.27 (+3.48), SNSS: 0.55 (-0.01)

WAVE Life Sciences (WVE) in Focus: Stock Up 6.1% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:35AM CDT
WAVE Life Sciences Ltd. (WVE) was a big mover last session, as the company saw its shares rise over 6% on the day.
WVE: 20.73 (+0.71), ANIP: 56.27 (+3.48)

GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:15AM CDT
GTx, Inc. (GTXI) shares rose almost 18% in the last trading session.
GTXI: 0.60 (unch), ANIP: 56.27 (+3.48)

Auris (EARS) Begins Phase III Study for Sudden Deafness
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:31AM CDT
Auris Medical (EARS) has started patient enrollment in a second pivotal phase III study (ASSENT) on AM-111 for the treatment of sudden deafness.
EARS: 4.00 (-0.05), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)

Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:13AM CDT
Emergent BioSolutions (EBS) announced that the FDA has accepted to review the company's sBLA for manufacturing BioThrax in Building 55.
EBS: 30.65 (-0.68), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:56AM CDT
Medivation (MDVN) announced data from a phase I/II study on pidilizumab for the treatment of pediatric with diffuse intrinsic pontine glioma.
MDVN: 59.26 (+0.37), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

Idera Pharmaceuticals (IDRA) Catches Eye: Stock Rises 8.3%
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:41AM CDT
Idera Pharmaceuticals, Inc. (IDRA) shares rose over 8% in the last trading session.
IDRA: 1.53 (+0.05), ANIP: 56.27 (+3.48)

Emergent (EBS) BioThrax Gets Orphan Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:48AM CDT
Emergent (EBS) announced that BioThrax was granted Orphan Drug status in the U.S.
EBS: 30.65 (-0.68), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isinwheel's 2027 E-Mobility Pitch: Beyond Resolutions

Embracing the E-Mobility Shift Here we are at the tail end of 2026, and isinwheel is riding high on the wave of New Year resolutions with their hefty e-mobility lineup. It's not just about buying the gear—it's about tackling our reliance on gas-guzzlers with electric scooters and bikes as our trusty steeds. "Reduce car trips? More greenery in your commute? These aren't...

Strategic Leap: Context Labs Sets Roots in Abu Dhabi

Breaking New Ground in AI Infrastructure Well, folks, we're witnessing an intriguing strategic move here that could potentially reshape the AI landscape across the MENA region. Context Labs, the masterminds behind the AI Data Infrastructure, have roped in a powerful ally in the form of 22/x, a frontrunner in the Abu Dhabi investment scene. And no, this isn't just about...

Why Accurate HVAC Load Calculations Matter

By Owen Jenkins Updated Nov 1, 2026 Category News Views 278

Beyond Square Footage: Critical HVAC Considerations When it comes to heating and cooling your home, simply considering its square footage is like trying to predict the weather with nothing but a coin flip. Bob Schmid, an HVAC guru from Ocean View, NJ, pulls back the curtain on why the details really matter in determining the most efficient and effective HVAC setup for any...

Smart Salary Moves for S Corp Owners: Riggs Unpacks Insights

Decoding the S Corp Salary Dance How much salary should the savvy owners of S corporations draw? It ain't a simple task or one-size-fits-all deal, folks. David Riggs spills the beans on HelloNation, sharing insights on this complex tango between drawing wages and raking in shareholder distributions. In the end, it’s about playing by the IRS rules—or risking a penalty...

Perion Acquisition: Affle's Bold Leap in Ad Tech

Affle's Strategic Acquisition of Perion Jumpin' through another hoop, Affle is gearing up to snag Perion in a hefty deal valued at about $420 million. For those of you not knee-deep in the ad tech sandbox, Affle—trading on the NSE as AFFLE—is aiming to ramp up its AI-driven conversion game by absorbing Perion, a veteran in the omnichannel advertising realm. "This...

One Stop Swap eyes school fundraising for growth

Transforming Fundraising with a Marketplace Twist Sometimes the real treasures are not tucked in textbooks but found in cluttered closets and basements. Enter One Stop Swap with a big idea—they're cooking up a fundraising strategy for schools that could shake things up by helping families sell their unused stuff. It's got that grassroots vibe with the potential to carve...

Afghanistan Claims Hong Kong Sixes in Thrilling Run Chase

Afghanistan's Dazzling Triumph Brace ourselves, because what just unfolded in the Hong Kong Sixes 2026 is nothing short of spectacular. Afghanistan's cricket team penned a brand-new chapter in the game's history by overcoming Australia in a pulsating final to capture their maiden Hong Kong Sixes title. Imagine this: chasing a formidable target of 116, they wrapped up the...

Ceva's Wireless IP Dominance Amid AI Device Surge

Keeping the Wireless IP Crown Against All Odds Look, I've seen dominance play out in the markets over the years, but Ceva’s stranglehold on the wireless interface IP market is something fierce. They've got a whopping 68% market share, and folks, that’s 12 times their closest competitor. Talk about leaving the competition eating dust! For a field growing at a solid...

Lily Toxicity in Cats: Urgent Action Matters

Understanding the Severity of Lily Toxicity Ah, lilies. They might look pretty on your dining table, but if you’ve got a feline prowling around your house, these beauties could be a silent cat killer. In the animal-medicine world, this isn’t just another cautionary tale; it's a full-blown call to arms for cat owners. Dr. Ashley Wheatley, a veterinary expert out of...

Aiper’s Black Friday Pool Deals Make a Splash

Black Friday: A Pool Owner's Break It’s not every day you stumble upon savings like these—Aiper is throwing some meaty discounts this Black Friday, saving pool owners up to a juicy $550 off robotic cleaners. Imagine that! For anyone with a pool to maintain, these deals might just be the ticket to less grunt work and more time lounging with a cold drink in hand....